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Background: Research has indicated that adverse effects terms are increasingly prevalent in the title, abstract or
indexing terms of articles that contain adverse drug effects data in MEDLINE and Embase. However, it is unknown
whether adverse effects terms are present in the database records of articles that contain adverse effects data of
medical devices, and thus, to what extent the development of an adverse effects search filter for medical devices
may be feasible.
Methods: A case study systematic review of a medical device was selected. The included studies from a systematic
review of the safety of recombinant human bone morphogenetic protein-2 (rhBMP-2) for spinal fusion were used in
the analysis. For each included study, the corresponding database record on MEDLINE and Embase was assessed to
measure the presence or absence of adverse effects terms in the title, abstract or indexing. The performance of
each potential adverse effects search term was also measured and compared.
Results: There were 82 publications (49 studies) included in the systematic review with 51 of these indexed on
MEDLINE and 55 on Embase. Ninety-four percent (48/51) of the records on MEDLINE and 95% (52/55) of the records
on Embase contained at least one adverse effects related search term. The wide variety of adverse effects terms
included in the title, abstract or indexing of bibliographic records, and the lack of any individual high-performing
search terms suggests that a combination of terms in different fields is required to identify adverse effects of
medical devices. In addition, the most successful search terms differed from the most successful terms for
identifying adverse drug effects.
Conclusions: The search filters currently available for adverse drug effects are not necessarily useful for searching
adverse effects data of medical devices. The presence of adverse effects terms in the bibliographic records of
articles on medical devices, however, indicates that combinations of adverse effects search terms may be useful in
search strategies in MEDLINE and Embase. The results, therefore, suggest that not only a search filter for the adverse
effects of medical devices is feasible, but also that it should be a research priority.
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Adverse effects are an important consideration in decision-
making by patients, clinicians and other health care profes-
sionals, policy makers and regulators. An adverse effect is a
‘harmful or undesirable outcome that occurs during or after
the use of a drug or intervention for which there is at least
reasonable possibility of a causal relation’ [1]. Although ad-
verse effects can occur with any intervention, methodo-
logical research into how to find information on adverse
effects has, to date, concentrated on identifying adverse ef-
fects of drug interventions [2]. The adverse effects of other
interventions such as surgery, medical devices, diagnostic
tests and physical interventions, however, are equally im-
portant. In particular, the importance of the adverse effects
of medical devices has been highlighted recently in the
press by articles on the potential harm from breast implants
and hip prostheses. Although the regulatory process for
medical devices is less stringent than for pharmaceutical
interventions, the adverse effects of medical devices can be
just as serious and can be an important factor in decision-
making for health care professionals, policy makers and
patients. Identifying the evidence on adverse effects for
medical devices is, therefore, paramount to inform health
care decisions.
Recent research has indicated that database searching
using adverse effects terms will now retrieve the majority
of articles on adverse drug effects (92%) [3,4]. However,
many of the terms that have proved useful are specific to
the adverse effects of drug interventions (for example,
adverse drug reaction, chemically induced, toxicity, drug
effects, drug induced, drug monitoring and drug hyper-
sensitivity). Similarly, the adverse effects search filters
developed to date have also focused on identifying ad-
verse drug effects [2].
A different approach may be required to searching for
adverse effects of non-drug interventions, and this is
confirmed by a recent study that tested the efficiency of
existing search filters in identifying adverse effects papers
related to medical devices. While these search filters
usually obtain around 92% of the relevant articles in
MEDLINE and 89% of the relevant articles in Embase, the
same filters only retrieved 74% of the relevant articles related
to medical devices in MEDLINE and 54% in Embase [5].
The development of search filters for adverse effects of
non-drug interventions and for medical devices, in par-
ticular, is therefore a key priority. The first stage of any
search filter development should be to assess its feasibil-
ity. Search terms related to adverse effects need to be
present in the bibliographic database records (in the
title, abstract or keywords fields) in order for any article
to be potentially retrievable by using adverse effects
terms in the database search strategy.
In this case study, we explore the presence or absence
of terms related to adverse effects in the bibliographicrecords of those articles included in a systematic review
of a medical device. In addition, we present those terms
that are the most useful for identifying the adverse
effects of this case study medical device.
Methods
A case study systematic review of the safety of recom-
binant human bone morphogenetic protein-2 (rhBMP-2)
was selected for analysis [6,7]. Here, rhBMP-2 is a med-
ical device (collagen sponge) that is widely used as an
alternative to iliac crest bone graft to promote fusion in
spinal surgery. RhBMP-2 is licensed as a medical device
with a pharmaceutical component and as with many
other medical devices requires a surgical procedure for
implementation.
This review was undertaken after a number of sources
raised concerns about the safety of rhBMP-2: during the
post-marketing period, several non-industry observational
studies reported adverse events possibly associated with
the use of rhBMP-2; the Food and Drug Administration
(FDA) issued a public health notification of potentially
life-threatening complications associated with swelling of
the neck and throat tissue after rhBMP-2 use in the cer-
vical spine; and a subsequent review of publicly available
data suggested an increased risk of complications and
adverse events for patients receiving rhBMP-2 that was 10
to 50 times higher than the original randomised controlled
trial (RCT) estimates. These sources identified a number
of specific adverse events of concern—some dependent
upon spinal location—such as dysphagia, retrograde ejacu-
lation, heterotopic bone formation and osteolysis. These
possible adverse effects of rhBMP-2 have received much
publicity, and a high-quality systematic review encom-
passing all the evidence was required to answer the many
ambiguities. The Centre for Reviews and Dissemination
(CRD) at the University of York was commissioned by
Yale University to conduct such as a review. The system-
atic review of the safety of rhBMP-2 included a search
of the following databases: BIOSIS Previews (1969–2008
only), CENTRAL, Embase, MEDLINE, PubMed, Science
Citation Index (SCI), ClinicalTrials.gov, the Database of
Abstracts of Reviews of Effects (DARE), the Health Tech-
nology Assessment (HTA) database and ToxFile. PubMed
was selected in addition to MEDLINE as PubMed includes
citations not included in MEDLINE as well as the
MEDLINE database itself. In addition to database search-
ing, various supplementary search methods were used that
included reference checking; contacting authors of key
papers; publishing a call for evidence in Spine Journal,
The Back Letter newsletter and on the Internet and setting
up automated ‘current awareness’ searches in Zetoc Alert
from the British Library and in MEDLINE to notify us
whenever new data matching our search criteria were
loaded onto the databases. The broad search strategy
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multiple synonyms, textwords and indexing terms used
for each facet. No adverse effects terms were applied to
the search strategy in order to try to maximise sensitivity
and allow a prospective analysis of the potential perform-
ance of adverse effects terms if they had been included. A
pragmatic decision was made to include disease terms
(spinal fusion) although it was appreciated that this may
have missed papers which referred to adverse effects of
the intervention in other bone conditions, or where spinal
fusion was not mentioned. No study design or date limits
were applied, and the full search strategy is published else-
where [6,7].
Inclusion criteria
All studies (RCTs and observational studies) of more than
ten adult participants that compared rhBMP-2 with any
other spinal fusion technique and reported adverse effects
were eligible for inclusion in the systematic review.
Analysis
The included references from this case study systematic
review formed the basis of the analysis. This review con-
tained 82 publications representing 49 studies. Of the 82
publications, 40 referred to 13 RCTs and one single-
armed study and the other 42 publications referred to 35
observational studies.
The first stage of the analysis was to check whether each
paper was listed in MEDLINE or Embase. MEDLINE and
Embase were selected as they are the most commonly
searched databases in systematic reviews and have been
evaluated for the availability of adverse drug effects terms
in the previous research [3,4,8]. In order to ascertain
whether each paper was contained in the databases, sev-
eral iterations using author names and words from the
title were used.
Adverse effects terms in the database records
For each database, the available papers were sorted ac-
cording to the following criteria:
1. The authors mentioned terms synonymous with
‘adverse effects’ in the title or abstract, potentially
enabling the papers to be found in an electronic
search. Generic adverse effects terms, such as
‘adverse events’, ‘side effects’, ‘complications’, ‘safe’
and ‘risk’ were accepted.
2. The authors mentioned specific named adverse
effects terms such as ‘swelling’, ‘dysphagia’ or ‘blood
loss’ in the title or abstract.
3. The papers had been indexed (using subject
headings or subheadings) with relevant terms for
adverse effects, potentially enabling the papers to be
found in an electronic search. Generic adverseeffects terms were accepted on the basis that they
could be considered synonymous with ‘adverse
effects’. Examples of included indexing terms are
‘postoperative complications/’ in MEDLINE and
‘device safety/’ in Embase. Examples of included
subheadings are ‘complications (co)’ in MEDLINE
and ‘side effect (si)’ in Embase.
4. The papers had been indexed with specific named
adverse effects terms such as ‘airway obstruction/’ in




There were 51 of the 82 included references on MED-
LINE (five were not identified at the time of the original
searches) and 55 of the 82 included references on
Embase (four were not identified at the time of the ori-
ginal searches). Seven of these included references from
Embase were duplicated within in Embase, and for the
purposes of this analysis, the duplicate records were not
included.
Adverse effects terms by search fields
The percentage of relevant records with either generic
or specific named adverse effects terms in the biblio-
graphic records (title, abstract or indexing) in MEDLINE
and Embase is presented in Table 1. The most com-
monly occurring adverse effects terms in the MEDLINE
records were generic adverse effects terms in the ab-
stract (73%), followed by specific adverse effects terms in
the abstract (61%) and then generic adverse effects sub-
headings (51%). In Embase, the most commonly occur-
ring adverse effects terms were specific named adverse
effects in the indexing (73%), followed by generic ad-
verse effects terms in the abstract (71%) and then spe-
cific adverse effects terms in the abstract (67%).
Overall, a search with generic adverse effects search
terms would retrieve 88% of the available records in
MEDLINE and 85% of the available records in Embase.
Searching with specific named adverse effects terms
would perform better in Embase than in MEDLINE
retrieving 92% of the records in Embase compared with
69% in MEDLINE.
A search with both generic and specific named adverse
effects in either MEDLINE or Embase would retrieve a
high proportion of the records available in each of the
databases (94% and 95%, respectively).
Individual search terms
The highest number of relevant records in MEDLINE was
retrieved by the subheading ‘adverse effects (ae)’ (47%),
followed by ‘complication’ in the abstract (31%), the indexing
term ‘postoperative complications/’ (27%), ‘complications’ in
Table 1 Adverse effects terms in the bibliographic







Generic adverse effects terms
Title 16% (8) 16% (9 plus 1
duplicate)
Abstract 73% (37) 71% (39 plus 4
duplicates)
Title or abstract 73% (37) 71% (39 plus 4
duplicates)
Indexing 31% (16) 35% (19)
Subheadings 51% (26) 62% (34)
EMBASE section headings NA 16% (9)
Any generic adverse effects
terms
88% (45) 85% (47 plus 5
duplicates)
Specific adverse effects terms
Title 18% (9) 20% (11 plus 1
duplicate)
Abstract 61% (31) 67% (37 plus 4
duplicates)
Title or abstract 61% (31) 67% (37 plus 4
duplicates)
Indexing 37% (19) 73% (40 plus 3
duplicates)
Any specific adverse effects
terms
69% (35) 82% (45 plus 5
duplicates)
Any adverse effects terms in
any field
94% (48) 95% (52 plus 5
duplicates)
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the abstract (27%) and then ‘blood loss’ in the abstract
(20%). A complete listing of the performance of individual
search terms in MEDLINE is presented in Additional file 1:
Table S1.
The highest number of relevant records in Embase was
retrieved by the subheading ‘complication (co)’ (49%),
followed by the term ‘complications’ in the abstract (31%);
the indexing term ‘pseudarthrosis/’ (24%); the subheading
‘adverse drug reaction (ae)’ (22%); the terms ‘blood loss’,
‘complications’ and ‘safety’ in the abstract (18%) and then
the indexing terms ‘bleeding/’ and ‘dysphagia/’ (18%). A
complete listing of the performance of individual search
terms in Embase is presented in Additional file 2: Table S2.
Discussion
This case study demonstrates the feasibility of developing
a generic search filter for adverse effects of medical de-
vices. Eighty-eight percent of MEDLINE records and 85%
of Embase records contained at least one generic search-
able term for adverse effects. With the addition of specific
named adverse effects terms, search performance could
potentially reach 94% in MEDLINE and 95% in Embase.The most successful individual adverse effects search
terms varied from those identified in similar research
using adverse drug effects case examples. There was a
greater tendency for terms such as ‘complication(s)’,
‘safe’, ‘safely’ or ‘safety’ to identify articles on the adverse
effects of medical devices than articles on drug effects.
The wide disparity of potentially useful search terms and
the lack of any one term successfully retrieving the ma-
jority of articles would suggest that any filter will need
to be developed using a large set of relevant records to
ensure that the optimal combination of search terms is
captured.
The main difference between MEDLINE and Embase
was the higher number of specific adverse effects terms
presents in Embase. While this undoubtedly improves
the sensitivity of Embase searches, it may be to the detri-
ment of the precision of Embase searches. The trade-off
between sensitivity and precision in database searching
is inevitable, and any search filter development will need
to consider this trade-off.
The relatively high proportion of records with specific
named adverse effects in the abstract or in the indexing in
Embase is reassuring given that adverse effects are often a
secondary or even tertiary outcome in primary studies.
Previous research in 2001 indicated that adverse drug ef-
fects terms are not present in the title, abstract or indexing
nearly a quarter of all relevant research and this problem is
more likely to be an issue in articles of non-drug inter-
ventions [8]. This finding led to recommendations that
searchers should not rely on adverse effects terms [9].
However, since 2001, there have been improvements in the
reporting of adverse effects in the title, abstract or indexing
in primary studies related to drug interventions [4]. This
may have resulted from efforts such as the CONSORT
extension for harms [10], calls from the Cochrane Adverse
Effects Methods Group (CAEMG) and in the published
literature [11-33]. These improvements may extend to the
reporting in articles on medical devices.
Interestingly, the results of this case study indicate that
adverse effects terms are more likely to be present in the
bibliographic records for medical devices than for drug
interventions [4,8]. However, it should be recognised that
this case study systematic review included many recent ar-
ticles and improvements in adverse effects reporting have
been identified over time [4]. It should also be noted that
these results might also be affected by the level of caution
demonstrated during the screening process in this case
study systematic review and the same level of attention
may not be present during routine screening of systematic
review search results.
Limitations
This analysis is only based on one case study systematic
review. This limits the generalisability of the results. This
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obtain unpublished data directly from the manufacturer.
The included studies also included an unusually high
number of conference abstracts and multiple publications
for the same study (particularly for the clinical trials). The
medical device is also rather atypical for a device in that it
has a pharmaceutical component. Thus, our findings may
be less generalizable.
Analysis of the precision of the search terms would
have been of interest, however, was beyond the scope of
this case study.
The usefulness of searching with specific terms is mea-
sured here, but this will only be applicable to those reviews
in which the searchers have a clear idea beforehand what
the potential key events are. This approach is not as useful
for unexpected or new events. However, in this case study
review, we have also demonstrated the value of generic ad-
verse effects terms which can be used in any review. More
research is required using more case study systematic
reviews. Nevertheless, our evaluation is an important first
step to guide systematic reviewers in an area which is
likely to gain greater prominence, given the heightened
public interest in safety of devices following recent scares.Conclusions
This case study demonstrates the presence of adverse
effects terms in the bibliographic records of articles on
medical devices. The search terms most successful in
identifying adverse effects of medical devices differed
from those used in adverse effects search filters for drug
interventions. Consequently, creating a search filter for
adverse effects of medical devices is feasible and should
be a research priority.Additional files
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